These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15279565)

  • 1. Pharmacological aspects of (-)-deprenyl.
    Magyar K; Pálfi M; Tábi T; Kalász H; Szende B; Szöko E
    Curr Med Chem; 2004 Aug; 11(15):2017-31. PubMed ID: 15279565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-deprenyl: pharmacological spectrum of its activity.
    Magyar K; Szende B; Jenei V; Tábi T; Pálfi M; Szöko E
    Neurochem Res; 2010 Dec; 35(12):1922-32. PubMed ID: 20725780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular pharmacology of L-deprenyl.
    Gerlach M; Riederer P; Youdim MB
    Eur J Pharmacol; 1992 Jun; 226(2):97-108. PubMed ID: 1639115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of selegiline against selective neurotoxins].
    Magyar K
    Vopr Med Khim; 1997; 43(6):504-14. PubMed ID: 9503567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacology of selegiline.
    Magyar K
    Int Rev Neurobiol; 2011; 100():65-84. PubMed ID: 21971003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].
    Pálfi M; Szökó E; Kálmán M
    Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
    Klegeris A; McGeer PL
    Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of MAO-B inhibitors on MPP+ toxicity in Vivo.
    Wu RM; Chen RC; Chiueh CC
    Ann N Y Acad Sci; 2000; 899():255-61. PubMed ID: 10863544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.
    Finnegan KT; Skratt JJ; Irwin I; DeLanney LE; Langston JW
    Eur J Pharmacol; 1990 Aug; 184(1):119-26. PubMed ID: 2120076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neuroprotective and neuronal rescue effects of (-)-deprenyl.
    Magyar K; Szende B; Lengyel J; Tarczali J; Szatmáry I
    J Neural Transm Suppl; 1998; 52():109-23. PubMed ID: 9564614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion.
    Mytilineou C; Leonardi EK; Radcliffe P; Heinonen EH; Han SK; Werner P; Cohen G; Olanow CW
    J Pharmacol Exp Ther; 1998 Feb; 284(2):700-6. PubMed ID: 9454817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake.
    Fang J; Yu PH
    Neuropharmacology; 1994 Jun; 33(6):763-8. PubMed ID: 7936114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
    Magyar K; Szende B; Lengyel J; Tekes K
    J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.